A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

Completed · Phase 2 · Has a placebo group

Conditions studied: Nonalcoholic Steatohepatitis (NASH)

In brief

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.

Key facts

Study ID
NCT04880031
Run by
GlaxoSmithKline
People needed
231
Starts
2021-09-30
Expected to finish
2025-10-27
Last updated by the study team
2026-07-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.